STOCK TITAN
  1. Home
  2. News
  3. MRK

Merck & Co Inc - MRK STOCK NEWS

Welcome to our dedicated news page for Merck & Co (Ticker: MRK), a resource for investors and traders seeking the latest updates and insights on Merck & Co.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Merck & Co's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Merck & Co's position in the market.

News
FDA Grants Priority Review to Merck’s Application for KEYTRUDA® (pembrolizumab) Plus Concurrent Chemoradiotherapy as Treatment for Patients With Newly Diagnosed High-Risk Locally Advanced Cervical Cancer
Rhea-AI Summary
Merck's supplemental Biologics License Application for KEYTRUDA in combination with radiotherapy and chemotherapy for cervical cancer has been accepted for priority review by the FDA. If approved, this would be Merck's third indication in cervical cancer and first in an earlier stage of the disease. The FDA has set a target action date of January 20, 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.05%
Tags
none
-
News
FDA Accepts for Priority Review Merck’s Supplemental New Drug Application for WELIREG® (belzutifan) in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC)
Rhea-AI Summary
Merck's supplemental new drug application for WELIREG, an oral HIF-2α inhibitor, has been accepted by the FDA for the treatment of advanced renal cell carcinoma (RCC) following previous therapies. The application has been granted priority review, and the FDA has set a target action date of January 17, 2024. Data from the LITESPARK-005 trial showed a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to everolimus, as well as a significant improvement in objective response rate (ORR). WELIREG is currently approved for the treatment of VHL disease. This development program includes four Phase 3 trials in RCC.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.43%
Tags
clinical trial
-
News
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) as Adjuvant Treatment for Adults with Non-Small Cell Lung Cancer at High Risk of Recurrence Following Complete Resection and Platinum-Based Chemotherapy
Rhea-AI Summary
Merck's anti-PD-1 therapy, KEYTRUDA, receives positive opinion for adjuvant treatment of NSCLC in Europe
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.67%
Tags
none
News
Merck Presents New Analyses Supporting the Promising Potential of Sotatercept, its Investigational Medicine for Adults with Pulmonary Arterial Hypertension (PAH)
Rhea-AI Summary
Merck presents new analyses of sotatercept for the treatment of pulmonary arterial hypertension (PAH) at ERS International Congress 2023. Exploratory analysis shows that treatment with sotatercept improves right heart size and function. Primary efficacy results from the STELLAR trial demonstrate significant improvement in 6-minute walk distance. SOTERIA study shows long-term safety and efficacy of sotatercept. Applications for regulatory approval of sotatercept have been submitted. Positive potential for sotatercept to transform the treatment of PAH.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.41%
Tags
none
-
News
European Commission Expands Merck’s ERVEBO® [Ebola Zaire Vaccine, (rVSVΔG-ZEBOV-GP) live] Indication to Include Children 1 Year of Age and Older
Rhea-AI Summary
Merck's ERVEBO receives expanded approval from the European Commission for immunization against Ebola Virus Disease caused by Zaire ebolavirus in individuals 1 year of age or older. The vaccine was previously approved for use in individuals 18 years of age or older. Merck has also established a global Ebola vaccine stockpile with UNICEF to support future outbreak preparedness and response efforts.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.36%
Tags
none
-
News
Long-Term Follow-up Data on Sustained Immunogenicity and Safety for GARDASIL®9 Published in Pediatrics
Rhea-AI Summary
New 10-year data on GARDASIL 9 vaccine shows no cases of certain HPV-related diseases in boys and girls vaccinated at ages 9-15 years. Antibody responses remained strong at 10 years. No serious adverse events reported.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
none
News
Merck to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
Rhea-AI Summary
Merck executives to participate in fireside chat at Morgan Stanley conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.12%
Tags
conferences
-
News
European Commission Approves KEYTRUDA® (pembrolizumab) Plus Trastuzumab and Chemotherapy as First-Line Treatment for HER2-Positive Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma Expressing PD-L1 (CPS ≥1)
Rhea-AI Summary
Merck's KEYTRUDA receives EU approval for first-line treatment of HER2-positive gastric cancer
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
none
-
News
Merck to Participate in the Citi 18th Annual BioPharma Conference
Rhea-AI Summary
Merck's Dr. Marjorie Green to speak at Citi BioPharma Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.97%
Tags
conferences
News
Merck Initiates Phase 3 Clinical Program for Oral PCSK9 Inhibitor Candidate MK-0616
Rhea-AI Summary
Merck initiates Phase 3 clinical program for MK-0616, an oral PCSK9 inhibitor, for the treatment of hypercholesterolemia. Phase 2b results showed significant LDL cholesterol reduction. Program plans to enroll approximately 17,000 participants across three global studies. Positive potential for MK-0616 to provide an important option for patients. No oral PCSK9 inhibitors currently available.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.69%
Tags
clinical trial
Stock MRK logo
Merck & Co Inc

NYSE:MRK

MRK Rankings

#24 Ranked by Market Cap
#1895 Ranked by Stock Gains
#1274 Ranked by Dividends

MRK Stock Data

318.50B
2.53B
0.05%
78.56%
0.77%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
US
Kenilworth

About MRK

Merck & Co., Inc. is an American multinational pharmaceutical company headquartered in Rahway, New Jersey, and is named for Merck Group, founded in Germany in 1668, of whom it was once the American arm. The company does business as Merck Sharp & Dohme or MSD outside the United States and Canada.